UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+7.72%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$4.73B
AUM Growth
+$538M
(+13%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
2.17%
Top 10 Holdings %
Top 10 Hldgs %
48.18%
Holding
712
New
102
Increased
142
Reduced
245
Closed
144
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$245M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$230M |
| 3 |
PDCE
PDC Energy, Inc.
PDCE
|
+$221M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$141M |
| 5 |
LSI
Life Storage, Inc.
LSI
|
+$87.5M |
Top Sells
| 1 |
First Horizon
FHN
|
+$179M |
| 2 |
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
|
+$146M |
| 3 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$70.5M |
| 4 |
Tower Semiconductor
TSEM
|
+$46.1M |
| 5 |
XM
Qualtrics International Inc. Class A Common Stock
XM
|
+$45.3M |
Sector Composition
| 1 | Healthcare | 32.5% |
| 2 | Technology | 15.54% |
| 3 | Financials | 12.09% |
| 4 | Real Estate | 8.52% |
| 5 | Materials | 5.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Amylyx Pharmaceuticals
AMLX
$937M
| $841K | 0.02% |
+39,000
| New | +$841K |
|
|
MORF
377
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $839K | 0.02% |
14,635
-15,917
| -52% | -$913K |
|
378
RH
RH
$4.51B
| $824K | 0.02% |
+2,500
| New | +$824K |
|
|
BHAC
379
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
| $819K | 0.02% |
78,575
-2,557
| -3% | -$26.7K |
|
380
California Resources
CRC
$4.14B
| $770K | 0.02% |
17,004
-955
| -5% | -$43.3K |
|
|
DBTX
381
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $767K | 0.02% |
199,200
+9,814
| +5% | +$37.8K |
|
382
Quanterix
QTRX
$210M
| $767K | 0.02% |
+34,000
| New | +$767K |
|
383
Disc Medicine
IRON
$2.15B
| $760K | 0.02% |
17,121
-28,629
| -63% | -$1.27M |
|
384
Aclaris Therapeutics
ACRS
$231M
| $757K | 0.02% |
73,014
-10,664
| -13% | -$111K |
|
385
Pultegroup
PHM
$27.9B
| $733K | 0.02% |
9,441
-48,152
| -84% | -$3.74M |
|
386
D.R. Horton
DHI
$53B
| $728K | 0.02% |
+5,985
| New | +$728K |
|
387
ZTO Express
ZTO
$15.1B
| $722K | 0.02% |
28,800
-53,558
| -65% | -$1.34M |
|
388
Schrodinger
SDGR
$1.43B
| $709K | 0.01% |
14,200
-3,881
| -21% | -$194K |
|
389
Precision BioSciences
DTIL
$58.6M
| $704K | 0.01% |
44,610
+14,082
| +46% | +$222K |
|
390
Monte Rosa Therapeutics
GLUE
$296M
| $688K | 0.01% |
100,478
+4,950
| +5% | +$33.9K |
|
|
ITOS
391
DELISTED
iTeos Therapeutics
ITOS
| $685K | 0.01% |
51,764
-17,536
| -25% | -$232K |
|
392
Viking Therapeutics
VKTX
$2.84B
| $679K | 0.01% |
41,905
-23,703
| -36% | -$384K |
|
393
Editas Medicine
EDIT
$251M
| $678K | 0.01% |
82,369
+18,319
| +29% | +$151K |
|
394
Charles River Laboratories
CRL
$7.97B
| $675K | 0.01% |
3,211
+158
| +5% | +$33.2K |
|
395
Praxis Precision Medicines
PRAX
$858M
| $671K | 0.01% |
38,903
+5,086
| +15% | +$87.7K |
|
|
CNTB
396
Connect Biopharma Holdings Limited Ordinary Shares
CNTB
$98.1M
| $670K | 0.01% |
603,900
+29,752
| +5% | +$33K |
|
397
Merck
MRK
$211B
| $668K | 0.01% |
5,790
-12,074
| -68% | -$1.39M |
|
398
AGNC Investment
AGNC
$10.8B
| $662K | 0.01% |
65,381
-81,571
| -56% | -$826K |
|
399
Wayfair
W
$11.3B
| $650K | 0.01% |
+10,000
| New | +$650K |
|
400
GE HealthCare
GEHC
$35.7B
| $637K | 0.01% |
7,835
-565
| -7% | -$45.9K |
|